The Daily Buyout
UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted

Dechra completes acquisition of pet stem-cell biotech Gallant

Dechra, a global veterinary specialty care company, completed its purchase of Gallant Pet, a U.S. animal-health biotech pioneering ready-to-use mesenchymal stromal cell therapies, marking its expansion into regenerative medicine. Terms were not disclosed.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →